| |
| |
Gene Symbol |
CAPZA1 |
| |
Aliases |
CAPPA1, CAPZ, CAZ1 |
| |
Entrez Gene ID |
|
| |
Gene Name |
Capping actin protein of muscle Z-line subunit alpha 1 |
| |
Chromosomal Location |
1p13.2 |
| |
HGNC ID |
|
| |
Summary |
CAPZA1 is a member of the F-actin capping protein alpha subunit family. This gene encodes the alpha subunit of the barbed-end actin binding protein. The protein regulates growth of the actin filament by capping the barbed end of growing actin filaments. [provided by RefSeq, Jul 2008]
|
| |
e!Ensembl
|
| Protein Information |
| |
Protein Name |
F-actin-capping protein subunit alpha-1, Cap Z, capZ alpha-1, capping actin protein of muscle Z-line alpha subunit 1, capping protein (actin filament) muscle Z-line, alpha 1 |
| |
Function |
|
F-actin-capping proteins bind in a Ca(2+)-independent manner to the fast growing ends of actin filaments (barbed end) thereby blocking the exchange of subunits at these ends. Unlike other capping proteins (such as gelsolin and severin), these proteins do not sever actin filaments. May play a role in the formation of epithelial cell junctions. |
|
| |
UniProt |
|
| |
PDB |
|
| |
Pfam |
| Pfam Accession |
Pfam ID |
| PF01267 |
F-actin_cap_A |
|
|
|
|
|
|
Interactions |
| | |
| STRING |
MINT |
IntAct |
| ENSP00000308741 |
|
O15516 |
|
| | |
View interactions
|
| |
| |
Associated Diseases
| Disease group | Disease Name | References |
| Cardiovascular Diseases |
| Hypertensive disease |
|
| Endocrine System Diseases |
| PCOS |
|
| Neoplasms |
| Esophagus Neoplasm |
|
|
|
References |
| |
| |
| Atiomo W, Khalid S, Parameshweran S, Houda M, Layfield R |
| Department of Obstetrics and Gynaecology, School of Human Development, University of Nottingham, and Nottingham University Hospitals, Nottingham, UK. william.atiomo@nottingham.ac.uk |
| BJOG. 2009 Jan;116(2):137-43. doi: 10.1111/j.1471-0528.2008.02041.x. |
Abstract
BACKGROUND: The exact causes of polycystic ovary syndrome (PCOS) are uncertain, and treatment could be improved. Discovery-based approaches like 'proteomics' may result in faster insights into the causes of PCOS and improved treatment. OBJECTIVES: To identify the number and nature of proteomic biomarkers found in PCOS so far and to identify their diagnostic and therapeutic potential. SEARCH STRATEGY: All published studies on proteomic biomarkers in women with PCOS identified through the MEDLINE (1966-2008), EMBASE (1980-2008) and the ISI web of knowledge (v4.2) databases. SELECTION CRITERIA: The terms 'polycystic ovary syndrome' and 'proteomic', 'proteomics', 'proteomic biomarker' or 'proteomics biomarker' without any limits/restrictions were used. DATA COLLECTION AND ANALYSIS: Original data were abstracted where available and summarised on a separate Microsoft Excel (2007) database for analysis. MAIN RESULTS: Seventeen articles were identified, of which 6 original papers and 1 review article contained original data. Tissues investigated included serum, omental biopsies, ovarian biopsies, follicular fluid and T lymphocytes. Sample sizes ranged from 3 to 30 women. One hundred and forty-eight biomarkers were identified. The biomarkers were involved in many pathways, for example the regulation of fibrinolysis and thrombosis, insulin resistance, immunity/inflammation and the antioxidant pathway. Eleven groups of biomarkers appeared to be independently validated. The individual sensitivities for the diagnosis of PCOS were reported for 11 named biomarkers and ranged from 57 to 100%. AUTHOR'S CONCLUSIONS: Proteomic biomarker discovery in PCOS offers great potential. Current challenges include reproducibility and data analysis. The establishment of a PCOS-specific biomarker data bank and international consensus on the framework of systematic reviews in this field are required. |
|
|
|
| |
| © 2019, Biomedical Informatics Centre, NIRRH |
National Institute for Research in Reproductive Health, Jehangir Merwanji Street, Parel, Mumbai-400 012
Tel: 91-22-24192104, Fax No: 91-22-24139412
|
